Tezepelumab
Tezepelumab
Tezepelumab (pronounced tez-e-pel-um-ab) is a monoclonal antibody designed for the treatment of asthma, particularly severe asthma that is uncontrolled by standard therapies. It is developed by Amgen and AstraZeneca.
Etymology
The name "Tezepelumab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "teze-" prefix is likely arbitrary.
Mechanism of Action
Tezepelumab works by blocking the action of a protein called thymic stromal lymphopoietin (TSLP), which is an upstream modulator in the inflammation process of asthma. By inhibiting TSLP, tezepelumab can prevent the release of pro-inflammatory cytokines and chemokines, and thus reduce inflammation and prevent asthma attacks.
Clinical Trials
Tezepelumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase 3 trials, it has shown to significantly reduce the annual asthma exacerbation rate in patients with severe, uncontrolled asthma.
Related Terms
External links
- Medical encyclopedia article on Tezepelumab
- Wikipedia's article - Tezepelumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski